Opiant Pharmaceuticals is a pharmaceutical company developing medicines for addictions and drug overdose. Co. has developed NARCAN® (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdose. Co.'s principal products include OPNT002 - Nasal Naltrexone for Alcohol Use Disorder; OPNT003 - Intranasal Nalmefene for Opioid Overdose Reversal; and OPNT004 - Drinabant Injection for Acute Cannabinoid Overdose. Co.'s pipeline also include Opioid Use Disorder, in which, Co. has in-licensed OPNT005, a heroin vaccine from Walter Reed Army Institute of Research. This is an early stage pre-clinical asset and requires further pre-clinical research before human testing. The OPNT stock yearly return is shown above.
The yearly return on the OPNT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the OPNT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|